DD 03
Alternative Names: DD-03Latest Information Update: 04 Apr 2023
At a glance
- Originator D and D Pharmatech
- Class Hepatoprotectants; Obesity therapies; Peptides
- Mechanism of Action Glucagon receptor agonists; Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Non-alcoholic steatohepatitis; Obesity
Most Recent Events
- 04 Apr 2023 Preclinical trials in Non-alcoholic steatohepatitis in South Korea (PO) (D and D Pharmatech pipeline, April 2023)
- 04 Apr 2023 Preclinical trials in Obesity in South Korea (PO) (D and D Pharmatech pipeline, April 2023)
- 22 Aug 2019 Early research in Non-alcoholic steatohepatitis in South Korea (PO), prior to August 2019 (D and D Pharmatech website, August 2019)